STOCK TITAN

Camp4 Therapeutics (NASDAQ: CAMP) insider to sell 1,738 shares

(Neutral)
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Camp4 Therapeutics Corp (CAMP) received a notice that affiliate Daniel Tardiff, through J.P. Morgan Securities LLC as agent, plans to sell 1,738 shares of common stock under Rule 144. The proposed sale is valued at approximately $8,275.55 with an anticipated sale date of August 19, 2026. The filing also notes an earlier 434-share ESPP issuance on July 2, 2026 for cash.

Positive

  • None.

Negative

  • None.
Shares proposed to be sold 1,738 shares Common stock to be sold under Rule 144 for the account of Daniel Tardiff
Approximate market value of shares $8,275.55 Value of 1,738 Camp4 Therapeutics common shares covered by the planned sale
Approximate date of sale 08/19/2026 Anticipated sale date for the 1,738 shares of common stock
ESPP issuance shares 434 shares Camp4 Therapeutics common stock issued via ESPP on 07/02/2026 for cash
Issuer phone 6176518867 Contact phone number for Camp4 Therapeutics Corporation
Rule 144 regulatory
"See the definition of "person" in paragraph (a) of Rule 144."
Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.
affiliate regulatory
"In addition, information shall be given as to sales by all persons... affiliate"
ESPP Issuance financial
"Common | 07/02/2026 | 434 ESPP Issuance | Camp4 Therapeutics"
Attorney in Fact regulatory
"J.P. Morgan Securities LLC, Workplace Solutions, as Agent and Attorney in Fact for Daniel Tardiff"

FAQ

What does the Form 144 filed for CAMP indicate about planned stock sales?

The Form 144 reports a planned sale of 1,738 shares of Camp4 Therapeutics common stock by affiliate Daniel Tardiff. J.P. Morgan Securities LLC will act as agent, with an estimated value of $8,275.55 and an anticipated sale date of August 19, 2026.

Who is selling Camp4 Therapeutics (CAMP) shares under this Form 144?

The notice covers shares for the account of Daniel Tardiff, identified as an affiliate of Camp4 Therapeutics. J.P. Morgan Securities LLC, Workplace Solutions, is acting as agent and attorney in fact to execute the planned Rule 144 sale of common stock.

How many CAMP shares are covered by the planned Rule 144 sale and what is their value?

The filing covers 1,738 shares of Camp4 Therapeutics common stock with an approximate market value of $8,275.55. These shares are expected to be sold on or about August 19, 2026 through J.P. Morgan Securities LLC on NASDAQ.

What recent equity issuance to the seller is disclosed for Camp4 Therapeutics (CAMP)?

The notice discloses a prior 434-share ESPP issuance of Camp4 Therapeutics common stock on July 2, 2026 for cash. This relates to shares acquired through an Employee Stock Purchase Plan (ESPP) before the planned Rule 144 sale.

On which market are the CAMP shares in this Form 144 expected to be sold?

The shares referenced in the Form 144 are Camp4 Therapeutics common stock listed on NASDAQ. J.P. Morgan Securities LLC is identified as the broker for the proposed sale of 1,738 shares with an estimated value of $8,275.55.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature